Zoetis discovers, develops and manufactures a diverse portfolio of animal health medicines and vaccines. It is complemented by diagnostic products, genetic tests, biodevices and a range of services which are designed to meet the needs of veterinarians, livestock farmers and pet owners. Zoetis has over 60 years’ experience in the animal health business and products are sold in well over 100 countries. In total it employs almost 10,000 people worldwide with annual revenue of $5.3 billion. Over 1,000 Zoetis employees are involved in R&D with 2,800 involved in helping and advising animal owners. They have over 25 manufacturing sites with three of these here in Ireland. The key ranges are vaccines, parasticides, anti-infectives, medicinal feed additives and other pharma products. All animals including beef, dairy, swine, poultry, sheep, fish, dogs, cats and horses are catered for with products and services. Relationships with Irish dairy farmers are supported by the technical and veterinary specialists who provide in-depth technical expertise and disease education. By having an on-the-ground presence, Zoetis can react quickly to local-market needs and be well positioned to help our customers continually increase their business productivity and sustain long-term success.
Zoetis now employs over 200 people in Ireland across four sites in Cherrywood, Tallaght, Rathdrum and Tullamore. In 2018, Zoetis acquired Cross Vetpharm Group’s Teatsealant Division, including its manufacturing site in the Dublin suburb of Tallaght where our market-leading bovine teat sealants Orbeseal® and Boviseal® are manufactured. This acquisition is designed to increase supply security for our key teat seal products. This acquisition demonstrates our continued commitment to building a steady and reliable global supply network for our customers; it will enable us to improve the supply chain for these brands and bring further value and supply security to you, the customer.